Assessing furmonertinib for lung cancer patients with specific mutations after surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase II, prospective, multi-centre study evaluates the efficacy and safety of furmonertinib in patients with epidermal growth factor receptor (EGFR) 20 insertion mutation positive stage IB-IIIA non-small cell lung carcinoma (NSCLC) following complete tumor resection. The study aims to enroll 20 subjects who will receive furmonertinib at a dosage of 160mg per day until disease recurrence, death, or intolerability, with a maximum treatment duration of three years. The primary endpoint is disease-free survival (DFS), while secondary endpoints include DFS rate, overall survival (OS), and changes in health-related quality of life (HRQoL). Additionally, peripheral blood ctDNA will be collected and analyzed throughout the study.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Provide informed consent prior to any study specific procedures;
* Male or female, aged at least 18 years;
* Complete surgical resection of the primary NSCLC is mandatory. All gross disease must have been removed at the end of surgery. All surgical margins of resection must be negative for the tumor;
* Patients must be classified post-operatively as Stage IB, II, or IIIA on the basis of pathologic criteria;
* Complete recovery from surgery and standard post-operative therapy (if applicable);
* Patient with EGFR 20 insertion mutation diagnosed histologically or cytologically, the reports must be issued or recognized by Tier 3A hospitals;
* ECOG PS of 0 to 1;
* For premenopausal women with childbearing potential, a pregnancy test must be performed within 14 days before the first dose, and the pregnancy test (blood or urine test) must be negative; female subjects must not be lactating;

Exclusion Criteria:

* Patients who have had only segmentectomies or wedge resections;
* Any prior anticancer therapy（excluding adjuvant platinum-based chemotherapy）;
* Patients currently receiving medications or herbal supplements known to be potent inducers of cytochrome P450 (CYP) 3A4;
* Treatment with an investigational drug within five half-lives of the compound or any of its related material;
* History of other malignancies, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer, or other solid tumors curatively treated with no evidence of disease for \> 5 years following the end of treatment;
* Any unresolved toxicities from prior therapy greater than CTCAE Grade 1 at the time of starting study treatment with the exception of alopecia and Grade 2, prior platinum-therapy related neuropathy;
* Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses; or active infection including hepatitis B, hepatitis C, and human immunodeficiency virus (HIV);
* Mean resting corrected QT interval (QTc) \>470 msec, obtained from 3 ECGs, using the screening clinic ECG Machine-derived QTc value;
* Any clinically important abnormalities in rhythm, conduction, or morphology of resting ECG;
* Any factors that increase the risk of QTc prolongation or risk of arrhythmic events, or unexplained sudden death under 40 years of age in first-degree relatives or any concomitant medication known to prolong the QT interval;
* Past medical history of ILD, drug-induced ILD, radiation pneumonitis which required steroid treatment, or any evidence of clinically active ILD;
* Inadequate bone marrow reserve or organ function;

Where it's running

• Sichuan cancer hospital
  Chengdu, Sichuan, China Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Vebreltinib plus furmonertinib in EGFR-mutated NSCLC with high PD-L1

  This study tests whether combining vebreltinib with furmonertinib can help people with advanced NSCLC that has EGFR mutations and very high PD-L1 expression.

  Recruiting Phase 1/2 Second Affiliated Hospital of Nanchang University · Nanchang, Jianxi · NCT07655622

• Amivantamab with platinum chemotherapy for metastatic EGFR‑mutant non‑small cell lung cancer

  This study will try giving amivantamab together with platinum chemotherapy to adults with metastatic NSCLC who have specific EGFR mutations to see how long their cancer stays controlled and how safe the treatment is.

  Recruiting at 11 sites Groupe Francais De Pneumo-Cancerologie · Aix-en-Provence and 15 other locations · NCT07563205

• Furmonertinib plus intrathecal chemotherapy and stereotactic radiotherapy for EGFR‑mutated NSCLC with brain parenchymal and leptomeningeal metastases

  This trial tries to see if taking furmonertinib with spinal‑fluid chemotherapy injections and focused brain radiotherapy helps people with EGFR‑mutated lung cancer who have both brain and leptomeningeal metastases.

  Recruiting at 3 sites Phase 2 Tianjin Medical University Cancer Institute and Hospital · Cangzhou, Hebei and 2 other locations · NCT07304739

• RC108 plus Furmonertinib as first-line treatment for EGFR-mutated, MET-positive advanced NSCLC

  This trial tests whether adding RC108 to Furmonertinib works better than Furmonertinib alone for adults with EGFR-mutated, MET-positive unresectable locally advanced or metastatic non-small cell lung cancer.

  Recruiting at 34 sites Phase 2 RemeGen Co., Ltd. · Beijing and 33 other locations · NCT06962865

• BEBT-109 treatment for lung cancer with specific mutations

  This study is testing a new drug called BEBT-109 to see if it can help people with a specific type of lung cancer that has certain mutations, especially those who haven't had much success with other treatments.

  Recruiting at 2 sites Phase 2 BeBetter Med Inc · Guangzhou, Guangdong and 1 other locations · NCT06706713

• High-dose furmonertinib alone or with chemotherapy for EGFR-mutant advanced non-small-cell lung cancer after progression on a third-generation EGFR-TKI

  This trial tests whether higher-dose furmonertinib, either by itself or combined with chemotherapy, helps people with EGFR-mutant advanced non-small cell lung cancer that progressed after a third-generation EGFR-TKI.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT06652048

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.